Research programme: cholesterol transport modulators - Gilead Sciences

Drug Profile

Research programme: cholesterol transport modulators - Gilead Sciences

Alternative Names: CVT-10176; CVT-11130

Latest Information Update: 15 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CV Therapeutics
  • Developer Gilead Sciences
  • Class
  • Mechanism of Action Apolipoprotein A I stimulants; ATP binding cassette transporter 1 stimulants; Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Tangier disease

Most Recent Events

  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
  • 15 Jun 2007 This programme is still in active development
  • 06 Jan 2000 Preclinical development for Atherosclerosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top